---
reference_id: "PMID:41369864"
title: Mantle cell lymphoma transformation to CD19-negative classic Hodgkin lymphoma as a novel mechanism of escape from CD19 chimeric antigen receptor T cell therapy.
authors:
- Yu Y
- Bayerl M
- Mineishi S
- Washburn E
journal: J Hematop
year: '2025'
doi: 10.1007/s12308-025-00675-1
content_type: abstract_only
---

# Mantle cell lymphoma transformation to CD19-negative classic Hodgkin lymphoma as a novel mechanism of escape from CD19 chimeric antigen receptor T cell therapy.
**Authors:** Yu Y, Bayerl M, Mineishi S, Washburn E
**Journal:** J Hematop (2025)
**DOI:** [10.1007/s12308-025-00675-1](https://doi.org/10.1007/s12308-025-00675-1)

## Content

1. J Hematop. 2025 Dec 10;18(1):59. doi: 10.1007/s12308-025-00675-1.

Mantle cell lymphoma transformation to CD19-negative classic Hodgkin lymphoma as 
a novel mechanism of escape from CD19 chimeric antigen receptor T cell therapy.

Yu Y(1), Bayerl M(1), Mineishi S(2), Washburn E(3).

Author information:
(1)Department of Pathology, Penn State Health Milton S. Hershey Medical Center, 
500 University Ave, Hershey, PA, H17917033, USA.
(2)Department of Hematology-Oncology, Penn State Health Milton S. Hershey 
Medical Center, Hershey, PA, USA.
(3)Department of Pathology, Penn State Health Milton S. Hershey Medical Center, 
500 University Ave, Hershey, PA, H17917033, USA. 
ewashburn1@pennstatehealth.psu.edu.

Mantle cell lymphoma (MCL) is a mature B cell neoplasm characterized by the 
CCND1::IgH t(11;14) translocation. The process of MCL clonal evolution remains 
poorly understood. In this report, we describe a rare case of a patient with 
blastoid variant MCL who developed clonally related classic Hodgkin lymphoma 
(CHL), following CD19 chimeric antigen receptor T cell (CAR T cell) therapy. A 
65-year-old man was initially diagnosed with blastoid variant MCL with a 
concurrent TP53 deletion. He was treated with chemotherapy followed by CD19 CAR 
T cell therapy with significant clinical response. Eight months later, he 
developed a recurrence with numerous CD19-negative, pleomorphic cells with 
Hodgkin and Reed-Sternberg-like (HRS-like) phenotype. The previously described 
blastoid MCL component was eradicated. Fluorescence in situ hybridization (FISH) 
testing confirmed CCND1::IgH t(11;14) in the HRS-like tumor cells, indicating a 
clonal relationship to the original MCL. Loss of CD19 expression is a known 
mechanism of resistance in CD19 CAR T cell therapy in B cell lymphomas. A 
notable feature of the HRS-like cells in this case is the gain of markers 
associated with CHL, such as CD30 and CD15. This immunophenotypic shift 
highlights the concept of lymphoma plasticity, where the tumor cells evolve in 
response to selective pressures, such as CAR T cell therapy.

Â© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
part of Springer Nature.

DOI: 10.1007/s12308-025-00675-1
PMID: 41369864 [Indexed for MEDLINE]

Conflict of interest statement: Declarations. Conflict of interest: The authors 
declare no competing interests. Ethical approval: For this type of study, formal 
consent is not required. The Institutional Review Board (IRB) does not require 
IRB approval for publication of case reports or images. Informed consent: For 
this type of study, informed consent is not required. Consent for publication: 
Consent for publication was obtained from the patient included in the report.